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twice per year were considered to have frequent hypos. Logistic regression was
used to evaluate the link between obesity and frequent hypos, controlling for age,
gender, country, and insulin use. Generalized linear models quantified the rela-
tionship between health care use and patient characteristics, including obesity,
frequent hypos, and insulin use. RESULTS: Height and weight data were available
for 2,780 T2D patients in France, Germany, and the UK. Obesity was more common
among patients in Germany (51.0%) and the UK (53.4%) than France (43.9%, both
p.05); frequent hypos were more common in France (16.5%) and the UK (13.2%)
than Germany (8.2%, both p.05). Overall, patients with frequent hypos were more
likely to be obese (57.6% vs. 49.1%, p.01), female (40.6% vs. 32.7%, p.01), insulin
users (36.7% vs. 17.5%, p.001), and have HbA1c 7.0% (61.3% vs. 49.4% of those
reporting HbA1c, p.01) than other patients. Obesity and frequent hypos were
associated after adjusting for covariates (OR 1.27, p.05). Multivariable models of
health care use showed frequent hypos were associated with more physician and
ER visits, and obesity was associated with more physician visits and hospitaliza-
tions (all p.05). CONCLUSIONS:Obese patients are at increased risk for moderate/
severe hypoglycemia, and both obesity and hypoglycemic events are associated
with more health care use. Improving management of obesity among T2D patients
may reduce the impact of diabetes on health care systems in Europe.
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OBJECTIVES: Diabetes therapies constitute one of the highest budgets allocated by
the Social Security Institution (SSI) each year in Turkey (within top 15). However, a
standard budget allocation plan for reimbursement of innovative drugs in diabetes
does not exist in Turkey. This study aims to offer a perspective for effective health
care budget planning for innovative drugs in diabetes for the SSI in order to achieve
patient access. METHODS: Total budget spent by SSI for diabetes treatment is
analyzed for the last three years. All treatment groups are defined for % unit and
Turkish Lira (TL) growth and those values are investigated relative to the total
diabetes budget. The current budget allocation structure for innovative drugs is
defined and a new methodology is offered. RESULTS: The highest budget in diabe-
tes is allocated for human insulin analogues with a total spending of 949,278,748 TL
(45.7%), followed by glitazones 388,374,291 TL (18.7%) and sulphonylurea
244,190,634 TL (11.8%). However, the total budget allocated for innovative drugs as
DPP-4 inhibitors and GLP-1 agonists is around 4.2%. The following steps for forward
planning of budgets are proposed: Analysis of each treatment option within the
same group with respect to effectiveness; defining reimbursement conditions
(price-volume) for each option based on effectiveness; analysis of each treatment
group with respect to effectiveness; defining budget allocated for each treatment
group based on effectiveness; biannual review of the budget realizations.
CONCLUSIONS: Re-evaluation of current therapies in terms of budget contribu-
tions and effectiveness may identify savings in SSI budget that could be freed up for
new treatment options becoming available. A stepwise approach including the
reevaluation of existing treatments in diabetes would be necessary in Turkey.
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OBJECTIVES: To evaluate the association between hypoglycaemic events (HEs) and
short-term disability (STD) using a retrospective case-control design among pa-
tients with diabetes receiving insulin therapy within a claims database.METHODS:
U.S. medical claims data was obtained from Thomson Reuters MarketScan Com-
mercial, Medicaid, and Health and Productivity Management databases from 1
January 2007 to 31 December 2009. Patients were selected if they were enrolled in a
health plan, eligible for STD for 12 months from the first date of an anti-diabetic
drug claim (index start date), and had 1 insulin claim. Analysis was performed
comparing patients who had at least 1 HE claim entered to those who had none.
HEs were defined based on ICD-9CM codes: 250.8, 251.0, 251.1, or 251.2 and probably
were serious/significant events entered on behalf of the patient. STD was mea-
sured by a binary indicator, number of cases, and total days absent from work. The
relationship between HEs and STD was evaluated before and after adjusting for
covariates. Regression models were used to adjust for known influential covariates
(duration of index period and Charlson Comorbidity Index) and fixed effects (sex,
age group, region, health plan type, employment status, diabetes type, prescription
regimen, and diabetic complications). RESULTS: There were 15,020 patients who
met the inclusion criteria with a mean index period of 2.4 years. 478 (3.2%) had
experienced 1 HEs and 3893 (25.9%) 1 STDs. The odds of having 1 STDs for
those with1 HEs was 74.7% higher than those with no HE (Adjusted OR: 1.747; 95%
CI: 1.429, 2.135). Patients reporting HEs had an average of 3.24 more days of absence
from work per year due to STDs than patients without HEs after adjusting for the
covariates. CONCLUSIONS: Results indicate a significant association between expe-
riencing HEs and the occurrence of STD among patients receiving insulin therapy.
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OBJECTIVES: To investigate the clinical effectiveness of increased physical activity
within adults with type 2 diabetes. METHODS: A systematic review was under-
taken to identify relevant randomized controlled trials (RCTs). MEDLINE, EMBASE
and the Cochrane databases were searched for RCTs up to December 2010 as well as
for systematic reviews to identify further RCTs. Reference lists were screened. For
inclusion into the review, studies had to compare increased physical activity to no
such an intervention with a follow-up period of at least 24 weeks. Patient-relevant
outcomes were predefined: all-cause mortality, cardiovascular morbidity and mor-
tality, health-related quality of life (HRQoL), end-stage renal disease, amputation,
retinal damages, hypoglycemia and adverse events. The risk of bias of each indi-
vidual study was assessed. RESULTS: Eight RCTs met the inclusion criteria and
reported on predefined outcomes. The following interventions were compared to
no such an intervention: endurance-training/strength-training or sessions with
mixed (aerobic and resistance) training. The studies included 1202 patients with a
mean age of 60 years. Only for the endpoints HRQoL and adverse events properly
reported results were found: 4 studies analyzed HRQoL but all used different out-
come measures, only one of the studies reported a statistically significant effect. 6
studies presented data on adverse events, 4 of them incompletely, 2 of them show-
ing no significant treatment effect CONCLUSIONS: Although there is a vast body of
literature on physical activity in adults with type 2 diabetes only 8 studies met the
inclusion criteria. Evidence on patient-relevant endpoints was scarce, as most
studies focused on HbA1c as their primary endpoint. We found no effect of in-
creased physical activity on HRQoL and adverse events in patients with type 2
diabetes. Conclusions for other endpoints could not be drawn. Thus, there is a great
demand for further studies with patient relevant primary endpoints.
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OBJECTIVES: Although Canada is reputed to be an international leader in diabetes
surveillance, there are gaps in knowledge about effectiveness of management,
resource utilization and health outcomes of people being treated for diabetes. The
objectives of this study were to follow a cohort of newly diagnosed persons with
diabetes in South-Western Ontario (SWO) over a 5-year period to document epide-
miology, management, baseline characteristics, clinical outcomes and resource
utilization. METHODS: Data from this cohort were compared to an age and gender
matched control group of individuals without diabetes. Regression analyses were
conducted to evaluate the impact of anti-diabetic medications on glycemic levels
and control after adjustment for age, gender and baseline HbA1c. RESULTS: A total
of 3861 individuals with newly diagnosed diabetes in 2002 were identified. The
mean HbA1c levels increased from 7.4% at time of diagnosis to 8.21% at the end of
the study in 2008. A similar trend was observed for fasting glucose levels (6.71% at
baseline to 7.41% in 2008). After controlling for covariates, regression analysis re-
sults indicates that continuous and intermittent use of anti-diabetic drugs com-
pared to no drug use had no significant impact on 2-year HbA1c levels. Further, the
results of our study indicate that a large proportion of the cases had uncontrolled
hypertension and hyperlipidemia. An interesting finding is that the average num-
ber of physician visits decreased from 7.9 per year at baseline to 4.8 at the end of 5
years in cases, whereas in controls, physician visits increased from an average of
6.8 at baseline to 7.4 five years later. Hospitalizations decreased over time from an
average of 6 days at baseline, to 2.4 days at the end of 5 years. CONCLUSIONS:
Consistent with other studies, these findings suggest that a minority of people with
diabetes in South-Western Ontario achieved optimal glycemic control.
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OBJECTIVES: In the UK, Oral Anti-Diabetic drugs “OAD” are administered to control
hyperglycaemia in type 2 diabetes when HbA1c exceeds 48mmol/mol. Guidelines
are designed to improve HbA1c response through regimen change. The aim is to
examine factors associated, especially HbA1c, with treatment regimen change in
clinical practice. METHODS: All patients who initiated an OAD (except rosiglita-
zone) in the GPRD database between 1/1/2006 and 25/2/2011 were included. HbA1c
was assigned to baseline and to each year following OAD initiation. The median
HbA1c is hereby reported using the mmol/mol scale. Each patient was classified as
augmenter, switcher, discontinuer or control (no change). This status was updated
at each year since OAD initiation; multinomial logistic regression models were
used to assess factors associated with treatment change; the odds ratios “OR” (with
95% confidence interval) represent the relative likelihood of change versus no
change.RESULTS:Of 63060 patients 34737 had HbA1c recorded around 1 year since OAD
initiation. HbA1c at one year was associated with treatment changes at the same time,
beinghighest foraugmentationwith insulin (80mmol/mol), augmentationwithOAD(68),
switching (63) and lowest for discontinuation and controls (both 51). Similar results were
seen at subsequent years. At one year since OAD initiation, the adjusted regression model
confirmed the increased HbA1c and chance of augmentation (OR2.8 per 10mmol/mol
increase; 2.7-2.9), switch (OR2.4; 2.2-2.5) and discontinuation (OR1.1; 1.1-1.2). Baseline
use of gliclazide was also associated with increased augmentation (OR1.6; 1.3-2.0),
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